Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis South Atlantic, a US division of the generic pharmaceutical company Actavis, has opened new analytical and R&D laboratories to expand the company's R&D efforts for controlled release and other technically difficult generic pharmaceutical products.
Subscribe to our email newsletter
The new analytical labs have been expanded by 3,000 square feet and the new R&D labs have been expanded by 1,500 square feet. As part of the Sunrise, Florida expansion, appropriate office space was also added to support both of the lab expansions.
Recently launched Actavis South Atlantic products in the US include Bupropion XL and SR, the generic equivalents of Glaxosmithline’s Wellbutrin XL and SR as well as Nifedipine ER, the generic equivalent of Bayer’s Adalat CC.
Doug Boothe, CEO of Actavis US, said: “Actavis in the US is focused on our vision and commitment to be on the cutting edge of new technology. The expansion of our South Atlantic R&D facility ensures that we remain well-positioned to develop and manufacture XL and continuous release drugs.”